Does the pharmacological class effect between the different luteinizing hormone releasing hormone analogues used in the treatment of prostate cancer have to be assumed?

Vilar-González, Santiago; Maldonado-Pijuan, X.; Andrés-García, I.

doi:10.1016/s2173-5786(10)70190-6

Cited by 5 publications

(7 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Maintenance of QoL and reduction in symptoms are important patient-centric outcomes, but direct comparative studies have not included these as endpoints, and improvement in LUTS have been shown with some but not all GnRH agonists. A similar analysis to the present review was published in 2010 and concluded that there was not enough evidence to support an assumed class effect amongst GnRH agonists [95]. Since then, insufficient novel data have emerged to warrant a change in this conclusion.…”

Section: Discussionsupporting

confidence: 75%

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Bolton

Lynch

2018

BJU International

View full text Add to dashboard Cite

To review direct comparative studies of the gonadotrophin-releasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. In June 2017, the following searches were performed independently by two reviewers in PubMed: (i) 'prostate cancer' and 'triptorelin' and 'leuprorelin', (ii) 'prostate cancer' and 'triptorelin' and 'goserelin', and (iii) 'prostate cancer' and 'goserelin' and 'leuprorelin', without time restriction. Duplicates were deleted. Relevant conference abstracts were also screened. A total of 16 direct comparative trials were identified: 12 reported on efficacy outcomes, four on safety/tolerability, and five on the convenience of administration/user perceptions. These studies are restricted in terms of patient numbers, formulations assessed, and endpoints measured; none were adequately powered for survival outcome measures. Studies reporting on efficacy endpoints did not show major differences in the ability of these GnRH agonists to reduce levels of testosterone or prostate-specific antigen. Some studies suggest differences in short- or long-term testosterone control, the rate of injection site adverse events, and patient/healthcare professional perceptions, but definitive conclusions cannot be drawn from the existing evidence. Few direct comparative trials of GnRH agonists have been conducted. Whilst GnRH agonists provide a similar castration effect, there is not enough evidence to show that GnRH agonists are equivalent.

show abstract

Section: Discussionsupporting

confidence: 75%

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Bolton

Lynch

2018

BJU International

View full text Add to dashboard Cite

show abstract

“…However, there is also information against this correlation with PC presentation profile 10 . At present, radiotherapy with HD addition is the standard of care in high-risk PC 44 . A clear benefit has been corroborated in cancer-specific survival, OS, and in clinical relapse-free survival, BRFS, and MDFS 44 .…”

Section: Discussionmentioning

confidence: 99%

“…At present, radiotherapy with HD addition is the standard of care in high-risk PC 44 . A clear benefit has been corroborated in cancer-specific survival, OS, and in clinical relapse-free survival, BRFS, and MDFS 44 . HD can be neoadjuvantly, concomitantly, or adjuvantly administered.…”

Section: Discussionmentioning

confidence: 99%

“…HD can be neoadjuvantly, concomitantly, or adjuvantly administered. In high-risk patients, it is common to start it in the neoadjuvant setting to continue concomitantly and adjuvantly for a prolonged period (for a total of 1.5-3 years) 44 . The rationale to combine HD with radiation therapy in the neoadjuvant setting lies in several factors: Prostatic volume debulking, which allows for doses to be increased without so much toxicity, tumor hypoxia reduction, which increases radiosensitivity, cell cycle slowing, which would result in decreased cell repopulation during radiation therapy, and finally, an apoptosis direct effect on tumor cells through an immunomodulation phenomenon 45 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between aspirin, radiation therapy, and hormone deprivation in prostate cancer

Vilar-González¹

2022

GAMO

View full text Add to dashboard Cite

Systematic review of studies published in PubMed about the relationship between prostate cancer and anticoagulants, especially aspirin. We analyze the role that their association with radiation and hormone deprivation and his possible synergistic effect in treatment. We describe bibliographic evidence of possible association between aspirin use and the onset, development and mortality by prostate cancer. Continue delving into the pathophysiological mechanisms involved. Finally, we describe and discuss the works related to the association between anticoagulants, radiation and hormone deprivation. Randomized trials are guaranteed, taking into account disease-related, patients and therapies factors, in order to obtain unbiased evidence of their likely relationship. Once confirmed the hypothesis of its synergistic effect, in prevention and/or in adjuvant treatment setting of prostate cancer, it opens up a whole range of future possibilities of great impact in the management of this prevalent disease. (creativecommons.org/licenses/by-nc-nd/4.0/).

show abstract

“…Se resumen los resultados extraídos de ensayos clínicos comparados o de metaanáli-sis, con el fin de obtener el mayor grado posible de evidencia científica. Se han encontrado 3 ensayos clínicos que compararon un análogo de la LHRH frente a dietiletilbestrol 11 , orquiectomía 12 o castración quirúrgica 13 ; 3 ensayos clínicos que compararon directamente varios análogos entre sí en formulación mensual 14---16 : 3 ensayos clínicos en formulación semestral que no compararon directamente análogos entre sí 17---19 , un metaanálisis 20 y una revisión sistemática actualizada en 2010 21 . Se han descartado revisiones adicionales anteriores que quedan englobadas en las 2 últimas referencias.…”

unclassified

Análogos de la hormona liberadora de gonadotropinas en cáncer de próstata: ¿podemos considerarlos en realidad equivalentes?

Alcaraz

2013

Actas Urológicas Españolas

View full text Add to dashboard Cite

Does the pharmacological class effect between the different luteinizing hormone releasing hormone analogues used in the treatment of prostate cancer have to be assumed?

Cited by 5 publications

References 57 publications

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Relationship between aspirin, radiation therapy, and hormone deprivation in prostate cancer

Análogos de la hormona liberadora de gonadotropinas en cáncer de próstata: ¿podemos considerarlos en realidad equivalentes?

Contact Info

Product

Resources

About